產(chǎn)品[
TIB-196 U266B1 人外周**細(xì)胞
]資料
如果您對該產(chǎn)品感興趣的話,可以
產(chǎn)品名稱:
TIB-196 U266B1 人外周**細(xì)胞
產(chǎn)品型號:
TIB-196
產(chǎn)品廠商:
美國標(biāo)準(zhǔn)生物品收藏中心（ATCC）
產(chǎn)品文檔:
無相關(guān)文檔
簡單介紹
TIB-196 U266B1 人外周LIN巴細(xì)胞，ATCC 細(xì)胞|細(xì)胞系|細(xì)胞株|腫瘤細(xì)胞|細(xì)胞|貼壁細(xì)胞|懸浮細(xì)胞|;細(xì)胞庫管理規(guī)范，提供的細(xì)胞株背景清楚，提供參考文獻(xiàn)和培養(yǎng)條件！
TIB-196 U266B1 人外周**細(xì)胞
的詳細(xì)介紹
TIB-196 U266B1 人外周LIN巴細(xì)胞
|
|
TIB-196?
|
|
$269.00
|
|
|
U266B1 [U266]
|
|
|
NK Nilsson
|
|
|
IgE; lambda light chain
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
|
suspension
|
|
|
Homo sapiens (human)
|
|
|
lymphoblast
|
|
|
Organ: peripheral blood
Disease: myeloma; plasmacytoma
Cell Type: B lymphocyte;
|
|
|
immunoglobulin; monoclonal antibody; interleukin 6 (interleukin-6, IL-6)
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
transfection host (Nucleofection technology from Lonza)
|
|
|
Amelogenin: X,Y
CSF1PO: 12,13
D13S317: 12
D16S539: 10
D5S818: 11,12
D7S820: 11,12
THO1: 5,7
TPOX: 8
vWA: 17
|
|
|
53 years *****
|
|
|
male
|
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 15%.
|
|
|
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 3 x 10 exp5 cells/ml and maintain between 1 x 10 exp5 and 1 x 10 exp6 cells/ml.
|
|
|
culture medium 95%; DMSO, 5%
|
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
recommended serum:ATCC 30-2020
|
|
|
1180: Nilsson K, et al. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin. Exp. Immunol. 7: 477-489, 1970. PubMed: 4097745
22377: Kawano M, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332: 83-85, 1988. PubMed: 3258060
32396: Kolanus W, et al. alphaLbeta2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1 a cytoplasmic regulatory molecule. Cell 86: 233-242, 1996. PubMed: 8706128
|
|
